You are here
P&T July 2012
Mortality rates for cardiovascular disease are higher in women than in men, but studies of women have been conducted less frequently. Current pharmacological and nonpharmacological treatment options for women with stable angina are reviewed.
Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.
FDA approvals, drug indications, and updates
Tazarotene (Fabior Foam) for acne; estradiol valerate and estradiol valerate/dienogest (Natazia) for heavy menstrual bleeding; and taliglucerase alfa (Elelyso) for Gaucher’s disease